^
    3d
    Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma. (PubMed, Front Immunol)
    RNA-seq results showed that the combined therapeutic approach synergistically reduces cell viability and promotes apoptosis through the inhibition of the MYC signaling pathway. Everolimus-gemcitabine combination exhibits synergistic antitumor activity, offering a potential therapeutic strategy for R/R PTCL.
    Retrospective data • Journal
    |
    ANXA5 (Annexin A5)
    |
    gemcitabine • everolimus
    5d
    Golidocitinib Combined With GemOx in RR PTCL (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    oxaliplatin • golidocitinib (DZD4205)
    5d
    Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • daunorubicin • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    7d
    Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review. (PubMed, Front Med (Lausanne))
    In order to improve the efficacy, recent studies have confirmed that the combination of etoposide (CHOPE regimen) on the basis of CHOP regimen can significantly improve the treatment response for newly diagnosed patients aged ≤ 65 years...The patient received four cycles of CHOPE regimen after surgical resection of the primary tumor and underwent PET/CT mid-term evaluation. Through this case, we aim to further explore the pathological diagnosis difficulties of such rare cases and preliminarily evaluate the clinical application value of CHOPE regimen.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • etoposide IV
    9d
    Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (clinicaltrials.gov)
    P2, N=155, Active, not recruiting, Daiichi Sankyo | Trial completion date: Sep 2025 --> Feb 2027
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8)
    |
    ALK positive • ALK negative
    |
    Ezharmia (valemetostat)
    10d
    Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=3000, Recruiting, Fudan University
    New trial • HEOR • Real-world evidence
    10d
    Primary ALK-Negative Anaplastic Large Cell Lymphoma Mimicking Septic Arthritis in a Diabetic Patient: Diagnostic and Therapeutic Challenges. (PubMed, J Vis Exp)
    A carefully staged treatment plan was employed, beginning with corticosteroids and etoposide, followed by liposomal mitoxantrone and the CD30-targeted antibody-drug conjugate brentuximab vedotin. The clinical course highlights the necessity of maintaining a high index of suspicion for lymphoma in refractory joint infections and demonstrates that individualized, stepwise therapy can achieve remission even in critically ill patients with aggressive ALCL. These findings provide valuable insights for improving the diagnosis and management of lymphoma cases that mimic infectious diseases.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK negative
    |
    etoposide IV • Adcetris (brentuximab vedotin) • Duoenda (mitoxantrone liposomal)
    10d
    Enteropathy-associated t-cell lymphoma presenting as refractory cutaneous ulcers in a 28-year-old male: a case report and literature review. (PubMed, Front Oncol)
    In patients with chronic diarrhea and refractory skin ulcers, celiac disease should be excluded, while cutaneous lesions should be recognized as potential paraneoplastic manifestations of an underlying lymphoma. Diagnostic delays-driven by anchoring bias and insufficient tissue sampling-are critical contributors to advanced disease at presentation and poor clinical outcomes.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • ITGAE (Integrin Subunit Alpha E)
    11d
    T-cell lymphoma arising during epcoritamab therapy for relapsed diffuse large B-cell lymphoma (PubMed, Rinsho Ketsueki)
    The clinical course was aggressive, and the patient died of the disease on the 13th day of hospitalization. This case highlights the potential for aggressive T-cell lymphoma to emerge during bispecific antibody therapy, a phenomenon that has also been noted in the context of CAR-T cell therapy.
    Journal
    |
    IL2 (Interleukin 2)
    |
    Epkinly (epcoritamab-bysp)
    16d
    BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (clinicaltrials.gov)
    P3, N=114, Enrolling by invitation, N.N. Petrov National Medical Research Center of Oncology
    New P3 trial
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone
    16d
    PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1, N=12, Terminated, Henan Cancer Hospital | Phase classification: P1/2 --> P1 | Trial completion date: Feb 2025 --> Aug 2025
    Phase classification • Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    Epidaza (chidamide) • parsaclisib (INCB50465)
    20d
    Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR) (clinicaltrials.gov)
    P=N/A, N=88, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New trial